Laura MBA - Si Bone CEO Director
| SIBN Stock | USD 18.44 0.97 5.55% |
Insider
Laura MBA is CEO Director of Si Bone
| Age | 58 |
| Address | 471 El Camino Real, Santa Clara, CA, United States, 95050 |
| Phone | 408 207 0700 |
| Web | https://si-bone.com |
Si Bone Management Efficiency
The company has return on total asset (ROA) of (0.1154) % which means that it has lost $0.1154 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2209) %, meaning that it created substantial loss on money invested by shareholders. Si Bone's management efficiency ratios could be used to measure how well Si Bone manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of February 2025, Return On Tangible Assets is likely to drop to -0.18. In addition to that, Return On Capital Employed is likely to drop to -0.21. At this time, Si Bone's Net Tangible Assets are very stable compared to the past year. As of the 25th of February 2025, Intangibles To Total Assets is likely to grow to 0, while Other Current Assets are likely to drop about 2.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Ehab Esmail | Orthofix Medical | 53 | |
| John Treace | Treace Medical Concepts | 53 | |
| Sam Park | Sight Sciences | 63 | |
| Jesse Selnick | Sight Sciences | N/A | |
| Mark Saxton | Neuropace | 59 | |
| Michael Favet | Neuropace | 54 | |
| Stacie Rodgers | Sight Sciences | N/A | |
| Rajbir Denhoy | Establishment Labs Holdings | 54 | |
| Janelle Strop | Tactile Systems Technology | N/A | |
| David MD | Sight Sciences | 55 | |
| MBA BS | Sight Sciences | N/A | |
| Daniel Owens | Treace Medical Concepts | 53 | |
| Jeffrey Bettinger | Establishment Labs Holdings | N/A | |
| Mark Quick | Orthofix Medical | N/A | |
| Victoria Vezina | Rapid Micro Biosystems | 56 | |
| Paul Rodio | Establishment Labs Holdings | 58 | |
| Lisa Paul | Pulmonx Corp | 61 | |
| Eric Pauls | Tactile Systems Technology | 49 | |
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| Martha Morrell | Neuropace | 67 | |
| John Ordway | Sight Sciences | N/A | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.12 |
Si Bone Leadership Team
Elected by the shareholders, the Si Bone's board of directors comprises two types of representatives: Si Bone inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SIBN. The board's role is to monitor Si Bone's management team and ensure that shareholders' interests are well served. Si Bone's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Si Bone's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Saqib Iqbal, Director Relations | ||
| Anshul Maheshwari, Chief Officer | ||
| Aimee Einstein, Vice Culture | ||
| Daniel Cher, Senior Affairs | ||
| Carlton Reckling, Chief Medical Officer and Vice President Medical Affairs | ||
| Michael Pisetsky, General Counsel and Chief Compliance Officer | ||
| Laura MBA, CEO Director | ||
| Nikolas Kerr, Strategy Product | ||
| Jeffrey Dunn, Executive Chairman | ||
| Scott Yerby, Vice President CTO | ||
| Jeff Bertolini, Senior Technology | ||
| Michael JD, Secretary Officer | ||
| Joseph Powers, VP Marketing | ||
| Anthony Recupero, Chief Commercial Officer |
SIBN Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Si Bone a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.24) % | ||||
| Operating Margin | (0.19) % | ||||
| Current Valuation | 620.8 M | ||||
| Shares Outstanding | 41.94 M | ||||
| Shares Owned By Insiders | 3.50 % | ||||
| Shares Owned By Institutions | 98.55 % | ||||
| Number Of Shares Shorted | 1.02 M | ||||
| Price To Book | 4.44 X |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Si Bone. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in SIBN Stock, please use our How to Invest in Si Bone guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Si Bone. If investors know SIBN will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Si Bone listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share | Quarterly Revenue Growth 0.186 | Return On Assets | Return On Equity |
The market value of Si Bone is measured differently than its book value, which is the value of SIBN that is recorded on the company's balance sheet. Investors also form their own opinion of Si Bone's value that differs from its market value or its book value, called intrinsic value, which is Si Bone's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Si Bone's market value can be influenced by many factors that don't directly affect Si Bone's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Si Bone's value and its price as these two are different measures arrived at by different means. Investors typically determine if Si Bone is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Si Bone's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.